A novel vaccine composed of cyclic GMP-AMP (cGAMP) (a STING agonist) and adsorbed tumor-associated antigens was developed to activate the STING pathway, enhancing the efficacy of immunotherapy and significantly preventing the recurrence and metastasis of HCC (58) (Table 2). This evidence concerns the gene STING1 and hepatocellular carcinoma.